Technical Analysis for ARRY - Array BioPharma Inc.

Grade Last Price % Change Price Change
grade C 13.19 1.70% 0.22
ARRY closed up 1.7 percent on Wednesday, January 17, 2018, on 1.45 times normal volume.
19 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ARRY trend table...

Date Alert Name Type % Chg
Jan 17 MACD Bearish Signal Line Cross Bearish 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 17 Inside Day Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Stochastic Sell Signal Bearish 1.70%
Jan 16 Wide Bands Range Expansion 1.70%
Jan 16 Down 3 Days in a Row Weakness 1.70%
Jan 12 Slingshot Bullish Bullish Swing Setup -3.79%
Jan 12 Wide Bands Range Expansion -3.79%
Jan 12 Overbought Stochastic Strength -3.79%

Older signals for ARRY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Is ARRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 17 EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
Jan 17 FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact The Firm
Jan 16 Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium
Jan 12 ARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in Class Action– ARRY
Jan 12 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
Jan 11 The Klein Law Firm Reminds Shareholders of a Class Action Commenced on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)
Jan 10 Today’s Research Reports on Trending Tickers: Array BioPharma and Nektar Therapeutics
Jan 10 Stocks Showing Market Leadership: Array Biopharma Earns 91 RS Rating
Jan 9 Array BioPharma (ARRY) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
Jan 9 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
See more ARRY news...
Indicators
Indicator Value
52 Week High 14.4
52 Week Low 6.73
Average Volume 3,099,063
200-Day Moving Average 9.8225
50-Day Moving Average 11.7485
20-Day Moving Average 12.7318
10-Day Moving Average 13.4005
Average True Range 0.6767
ADX 23.27
+DI 25.77
-DI 23.02
Chandelier Exit (Long, 3 ATRs ) 12.3699
Chandelier Exit (Short, 3 ATRs ) 12.5651
Upper Bollinger Band 14.7314
Lower Bollinger Band 10.7322
Percent B (%b) 0.61
BandWidth 31.411112
MACD Line 0.5556
MACD Signal Line 0.5682
MACD Histogram -0.0126
Fundamentals Value
Market Cap 2.26 Billion
Num Shares 171 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -18.32
Price-to-Sales 41.12
Price-to-Book 153.97
PEG Ratio -1.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.97
Resistance 3 (R3) 13.96 13.68 13.84
Resistance 2 (R2) 13.68 13.48 13.69 13.80
Resistance 1 (R1) 13.44 13.36 13.56 13.45 13.75
Pivot Point 13.16 13.16 13.23 13.17 13.16
Support 1 (S1) 12.92 12.96 13.04 12.93 12.63
Support 2 (S2) 12.64 12.84 12.65 12.58
Support 3 (S3) 12.40 12.64 12.54
Support 4 (S4) 12.41